Polymed Biopharmaceuticals
Polymed Biopharmaceuticals is a drug discovery and development company leveraging AI and structural biology to design novel therapeutics for oncology and autoimmune diseases. Their innovation strategy focuses on tackling traditionally undruggable disease drivers through advanced technologies like protein degradation and covalent bonding modalities. The company aims to create first-in-class and best-in-class medicines, with a dynamic and sustainable pipeline. They have experienced leadership with expertise in various therapeutic modalities including PROTACs and antibody-drug conjugates, and a history of bringing products to market. Polymed has secured multiple rounds of financing to support its development efforts.
Polymed Biopharmaceuticals
Polymed Biopharmaceuticals is a drug discovery and development company leveraging AI and structural biology to design novel therapeutics for oncology and autoimmune diseases. Their innovation strategy focuses on tackling traditionally undruggable disease drivers through advanced technologies like protein degradation and covalent bonding modalities. The company aims to create first-in-class and best-in-class medicines, with a dynamic and sustainable pipeline. They have experienced leadership with expertise in various therapeutic modalities including PROTACs and antibody-drug conjugates, and a history of bringing products to market. Polymed has secured multiple rounds of financing to support its development efforts.